問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2024-10-14

吳文正Wu, Wen-Jeng
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 3 個月

篩選

List

37Cases

2026-08-28 - 2032-02-19

Phase III

Not yet recruiting
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
  • Condition/Disease

    Urothelial Cancer, Urinary Bladder Neoplasms

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Not yet recruiting6Sites

2022-05-01 - 2024-08-16

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-11-01 - 2031-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2035-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2019-07-22 - 2030-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2018-10-30 - 2022-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4